Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01178216
Other study ID # Genentech-Ritux2010
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 2013
Est. completion date July 28, 2017

Study information

Verified date September 2018
Source Cedars-Sinai Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single center, Phase I/II, exploratory study has been modified to a safety/efficacy study providing all patients with IVIG and Rituximab. The trial will examine the safety and efficacy of human polyclonal IVIG 10%, when given at [2.0 gm/kgx2], + Rituximab 1gm to reduce donor-specific antibodies (DSA) to a level that is permissive for transplantation in 75 subjects (adults only ages >18 yrs) who are highly-HLA sensitized and are awaiting deceased donor kidney transplant. Once transplant offers are entertained, a donor-specific crossmatch will be performed. If acceptable crossmatches and DSA levels are seen, the patients will proceed to DD transplantation. Patients receiving transplants will receive an additional dose of IVIG at transplantation (within 10 days) and will receive additional doses of Rituximab 1g at 3M post transplant if DSA levels remain or become positive at 6M if de novo DSA occur. Patients who are desensitized and not transplanted at 9M after desensitization will have completed the study and can be treated as best judged by their physician.


Description:

Organ transplantation offers the only hope for a normal life for patients with end-stage renal disease on dialysis. For patients with antibodies to human leukocyte antigens (HLA), transplantation is extremely difficult or impossible since pre-formed antibodies will cause severe rejection and loss of transplanted organs. Intravenous gamma globulin (IVIG) can reduce or eliminate these antibodies in most patients and allow for successful transplantation. This breakthrough has allowed patients previously considered not transplantable to receive life-saving transplants. However, IVIG alone does not always eradicate the anti-HLA antibodies to a degree that will allow transplantation.

In this study, the investigators propose additional treatment with rituximab, a humanized antibody directed at the CD20 antigen that is present on most B-cells. Both IVIG and rituximab are approved by the U.S. Food and Drug Administration (FDA) for numerous immunologic disorders and Non-Hodgkin's lymphoma, respectively. However, neither is approved by the FDA for desensitization of highly-HLA sensitized transplant patients. A previously conducted pilot study demonstrated IVIG + Rituximab can fill an important gap in the current therapeutic approach for management of highly sensitized patients and may become the standard therapy.

Update: Study updated after observation that subjects transplanted after desensitization with IVIG alone experienced higher rates of antibody rejection and graft loss. The primary objective of this revised protocol will be to examine the safety and efficacy of IVIG 2gm/kg (maximum 140g) given on day#0 & day #30 plus Rituximab 1gm given on day #15. Transplanted patients will receive additional doses of Rituximab 1gm at 3 months post-transplant if donor specific antibody (DSA) levels remain or become positive or at 6M if de novo DSA occur. All transplanted patients who remain DSA negative, will not receive additional Rituximab. All transplanted patients will have a protocol biopsy at transplant and 12 months. All subjects will complete 5 visits in the pre-transplant phase of the study. Patients who are transplanted will have additional 5 post-transplant visits. The following are research-related procedures:

1. Rituximab infusion.

2. Kidney allograft biopsies (Intra-op, 12 months post-transplant)

3. Rituximab level, HACA levels

4. Immunologic biomarkers (CD19+, CD38+, CD27+)

Although the investigator commonly uses both treatment regimens at Cedars-Sinai Medical Center, only the IVIG treatment is considered to be standard of care for highly HLA-sensitized patients. The investigational component of this study is the addition of the rituximab. Currently the study has been amended to a safety and efficacy study focusing on decreasing HLA antibodies pre-transplant and minimizing DSA post-transplant.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date July 28, 2017
Est. primary completion date July 28, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. End-stage renal disease.

2. No known contraindications for therapy with IGIV10%/Rituximab.

3. Age 18-70 years at the time of screening.

4. PRA> 30% demonstrated on 3 consecutive samples, UNOS wait time sufficient to allow DD offers, history of sensitizing events, positive crossmatch with the intended donor.

5. Subject/Parent/Guardian must be able to understand and provide informed consent.

Exclusion Criteria:

1. Lactating or pregnant females.

2. Pediatric patients <18 years of age

3. Women of child-bearing age who are not willing or able to practice FDA-approved forms of contraception.

4. HIV-positive subjects.

5. Subjects who test positive for HBV infection [positive HBVsAg, HBVcAg, or HBVeAg/DNA] or HCV infection [positive Anti-HCV (EIA) and confirmatory HCV RIBA].

6. Subjects with active TB.

7. Subjects with selective IgA deficiency, those who have known anti-IgA antibodies, and those with a history of anaphylaxis or severe systemic responses to any part of the clinical trial material.

8. Subjects who have received or for whom multiple organ transplants are planned.

9. Recent recipients of any licensed or investigational live attenuated vaccine(s) within two months of the screening visit (including but not limited to any of the following:

- Adenovirus [Adenovirus vaccine live oral type 7]

- Varicella [Varivax]

- Hepatitis A [VAQTA]

- Rotavirus [Rotashield]

- Yellow fever [Y-F-Vax]

- Measles and mumps [Measles and mumps virus vaccine live]

- Measles, mumps, and rubella vaccine [M-M-R-II]

- Sabin oral polio vaccine

- Rabies vaccines [IMOVAX Rabies I.D., RabAvert])

10. A significantly abnormal general serum screening lab result defined as a WBC < 3.0 X 103/ml, a Hgb < 8.0 g/dL, a platelet count < 100 X 103/ml, , an SGOT > 5X upper limit of normal, and an SGPT >5X upper limit of normal range.

11. Individuals deemed unable to comply with the protocol.

12. Subjects with active CMV or EBV infection as defined by CMV-specific serology (IgG or IgM) and confirmed by quantitative PCR with or without a compatible illness.

13. Subjects with a known history of previous myocardial infarction within one year of screening.

14. Subjects with a history of clinically significant thrombotic episodes, and subjects with active peripheral vascular disease.

15. Use of investigational agents within 4 weeks of participation.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Rituxan
Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.

Locations

Country Name City State
United States Cedars-Sinai Medical Center Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
Stanley Jordan, MD Genentech, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Jordan SC, Peng A, Vo AA. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. Contrib Nephrol. 2009;162:13-26. doi: 10.1159/000170864. Epub 2008 Oct 31. Review. — View Citation

Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008 Jul 17;359(3):242-51. doi: 10.1056/NEJMoa0707894. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients That Underwent Transplantation This trial is designed to determine if Rituximab + IVIG can improve rates of transplantation for highly-HLA sensitized DD candidates on the UNOS waiting list over a 9M period of time after completion of treatment. 9 month
Secondary Number of Patients With Allograft Survival Graft survival in study participants 12 months
Secondary Reduction in Anti-HLA Antibodies Number of patients with a reduction in anti-HLA antibodies. 9 months
Secondary Number of Acute Rejection Episodes Number of rejection episodes in study participants 12 months
Secondary Number of Patients Reporting a Serious Infection Infection rate in study participants 12 months
Secondary Number of Adverse Events, Toxicity Assessments Adverse effects in study participants 12 months
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT03289650 - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Phase 3
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03257410 - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A